IO Biotech, Inc. (IOBT)
NASDAQ: IOBT · Real-Time Price · USD
0.7516
-0.0734 (-8.90%)
At close: Nov 19, 2025, 4:00 PM EST
0.7562
+0.0046 (0.61%)
Pre-market: Nov 20, 2025, 4:55 AM EST
IO Biotech Employees
IO Biotech had 80 employees as of December 31, 2024. The number of employees increased by 12 or 17.65% compared to the previous year.
Employees
80
Change (1Y)
12
Growth (1Y)
17.65%
Revenue / Employee
n/a
Profits / Employee
-$1,104,363
Market Cap
49.52M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 80 | 12 | 17.65% |
| Dec 31, 2023 | 68 | 11 | 19.30% |
| Dec 31, 2022 | 57 | 25 | 78.13% |
| Dec 31, 2021 | 32 | 21 | 190.91% |
| Dec 31, 2020 | 11 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
IOBT News
- 5 days ago - IO Biotech Reports Third Quarter 2025 Financial Results and Provides Business Highlights - GlobeNewsWire
- 7 days ago - IO Biotech Announces Participation in Upcoming Investor Conferences - GlobeNewsWire
- 12 days ago - IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC) - GlobeNewsWire
- 4 weeks ago - IO Biotech Presents Phase 3 Results for Cylembio® plus KEYTRUDA® (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025 - GlobeNewsWire
- 7 weeks ago - IO Biotech Provides Update Following Pre-BLA Meeting with FDA - GlobeNewsWire
- 2 months ago - IO Biotech Announces Late-Breaking Abstract in Advanced Melanoma Selected for Oral Presentation at ESMO Congress 2025 - GlobeNewsWire
- 2 months ago - IO Biotech, Inc. (IOBT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 3 months ago - IO Biotech Reports Second Quarter 2025 Financial Results and Provides Business Highlights - GlobeNewsWire